New Triple-Drug inhaler tested against standard asthma care

NCT ID NCT06372496

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study aims to see if a three-drug combination inhaler works better than the standard two-drug inhaler for adults whose asthma is not well controlled. It will involve about 1,366 participants and will measure improvements in lung function and asthma symptoms over one year. The goal is to help people with uncontrolled asthma breathe easier and have fewer flare-ups.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Centreville, Alabama, 35042, United States
GSK Investigational Site

Little Rock, Arkansas, 72205, United States
GSK Investigational Site

Newport Beach, California, 92663, United States
GSK Investigational Site

Newark, Delaware, 08901, United States
GSK Investigational Site

Clearwater, Florida, 33765-2150, United States
GSK Investigational Site

Florida City, Florida, 32819, United States
GSK Investigational Site

Miami, Florida, 15801, United States
GSK Investigational Site

Miami, Florida, 33126, United States
GSK Investigational Site

Miami, Florida, 33135, United States
GSK Investigational Site

Miami, Florida, 33173, United States
GSK Investigational Site

North Miami Beach, Florida, 33169, United States
GSK Investigational Site

Palm Springs, Florida, 33406, United States
GSK Investigational Site

Port Charlotte, Florida, 33952, United States
GSK Investigational Site

Tallahassee, Florida, 32308, United States
GSK Investigational Site

Normal, Illinois, 61761, United States
GSK Investigational Site

New Orleans, Louisiana, 20852, United States
GSK Investigational Site

Bangor, Maine, 04401, United States
GSK Investigational Site

Detroit, Michigan, 48202, United States
GSK Investigational Site

Warren, Michigan, 48088, United States
GSK Investigational Site

Missoula, Montana, 59804, United States
GSK Investigational Site

Papillion, Nebraska, 68046, United States
GSK Investigational Site

Brick, New Jersey, 08724, United States
GSK Investigational Site

Linwood, New Jersey, 08221, United States
GSK Investigational Site

New Windsor, New York, 12553, United States
GSK Investigational Site

Asheville, North Carolina, 28801, United States
GSK Investigational Site

Charlotte, North Carolina, 28273, United States
GSK Investigational Site

Greenville, North Carolina, 27834, United States
GSK Investigational Site

Winston-Salem, North Carolina, 27104, United States
GSK Investigational Site

Cincinnati, Ohio, 45231, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19140, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15241, United States
GSK Investigational Site

Rock Hill, South Carolina, 29732, United States
GSK Investigational Site

Spartanburg, South Carolina, 29303, United States
GSK Investigational Site

Beaumont, Texas, 77701, United States
GSK Investigational Site

Dallas, Texas, 75225, United States
GSK Investigational Site

Bellingham, Washington, 98225, United States
GSK Investigational Site

Buenos Aires, C1128AAF, Argentina
GSK Investigational Site

Buenos Aires, C1192AAW, Argentina
GSK Investigational Site

Buenos Aires, C1425BEN, Argentina
GSK Investigational Site

Buenos Aires, FVH1425, Argentina
GSK Investigational Site

Ciudad Autonoma de Buenos Aire, 1012, Argentina
GSK Investigational Site

Concepción del Uruguay, 3260, Argentina
GSK Investigational Site

Córdoba, X5003DCE, Argentina
GSK Investigational Site

Formosa, 3600, Argentina
GSK Investigational Site

Luján, 6700, Argentina
GSK Investigational Site

Luján de Cuyo, 5509, Argentina
GSK Investigational Site

Mar del Plata, 7600, Argentina
GSK Investigational Site

Mendoza, 5500, Argentina
GSK Investigational Site

Mendoza, 5577, Argentina
GSK Investigational Site

Mendoza, M5500, Argentina
GSK Investigational Site

Quilmes, 1878, Argentina
GSK Investigational Site

Rosario, 2000, Argentina
GSK Investigational Site

Rosario, S2000 DEJ, Argentina
GSK Investigational Site

Rosario, S2000DBS, Argentina
GSK Investigational Site

San Juan Bautista, 1888, Argentina
GSK Investigational Site

San Miguel de Tucumán, T4000AXL, Argentina
GSK Investigational Site

Santa Fe, 3000, Argentina
GSK Investigational Site

Bruce, Australian Capital Territory, 2617, Australia
GSK Investigational Site

Blacktown, New South Wales, 2148, Australia
GSK Investigational Site

Coffs Harbour, New South Wales, 2450, Australia
GSK Investigational Site

Kanwal, New South Wales, 2259, Australia
GSK Investigational Site

Sydney, New South Wales, 2035, Australia
GSK Investigational Site

Brisbane, Queensland, 4006, Australia
GSK Investigational Site

Osborne Park, Western Australia, 6017, Australia
GSK Investigational Site

Spearwood, Western Australia, 6163, Australia
GSK Investigational Site

Windsor, Ontario, N8X 1T3, Canada
GSK Investigational Site

Trois-Rivières, Quebec, G9A 4P3, Canada
GSK Investigational Site

Chancheng District, Foshan City, 528031, China
GSK Investigational Site

Liwan District, Guangzhou, 510160, China
GSK Investigational Site

North Street, Jiangmen City, 52900, China
GSK Investigational Site

Nanshan District, 518067, China
GSK Investigational Site

Zhuhai, 519099, China
GSK Investigational Site

Fukuoka, 802-0083, Japan
GSK Investigational Site

Fukuoka, 807-8555, Japan
GSK Investigational Site

Fukuoka, 816-0813, Japan
GSK Investigational Site

Fukuoka, 820-8505, Japan
GSK Investigational Site

Fukuoka, 832-0059, Japan
GSK Investigational Site

Gifu, 509-6134, Japan
GSK Investigational Site

Hiroshima, 730-0013, Japan
GSK Investigational Site

Hiroshima, 730-0853, Japan
GSK Investigational Site

Hiroshima, 733-0002, Japan
GSK Investigational Site

Hyōgo, 651-0053, Japan
GSK Investigational Site

Kagawa, 761-8073, Japan
GSK Investigational Site

Kagoshima, 890-0053, Japan
GSK Investigational Site

Kanagawa, 252-0143, Japan
GSK Investigational Site

Kumamoto, 860-8556, Japan
GSK Investigational Site

Kumamoto, 862-0965, Japan
GSK Investigational Site

Matsuyama, 790-0925, Japan
GSK Investigational Site

Miyagi, 980-0871, Japan
GSK Investigational Site

Miyazaki, 880-2112, Japan
GSK Investigational Site

Miyazaki, 889-4304, Japan
GSK Investigational Site

Nagaoka-Shi, 940-0087, Japan
GSK Investigational Site

Niigata, 950-0088, Japan
GSK Investigational Site

Okawa-shi, 831-0016, Japan
GSK Investigational Site

Ōita, Japan
GSK Investigational Site

Shinjuku-kuTokyo, 160-0021, Japan
GSK Investigational Site

Tokyo, 105-0001, Japan
GSK Investigational Site

Tokyo, 142-8666, Japan
GSK Investigational Site

Tokyo, 145-0063, Japan
GSK Investigational Site

Tokyo, 157-0066, Japan
GSK Investigational Site

Tokyo, 160-0017, Japan
GSK Investigational Site

Tokyo, 173-8606, Japan
GSK Investigational Site

Yokohama, 223-0053, Japan
GSK Investigational Site

Busan, 602 702, South Korea
GSK Investigational Site

Daegu, 41404, South Korea
GSK Investigational Site

Seongnam-si Gyeonggi-do, 13620, South Korea
GSK Investigational Site

Seoul, 02841, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 07061, South Korea
GSK Investigational Site

Seoul, 133-792, South Korea
GSK Investigational Site

Seoul, 158-710, South Korea
GSK Investigational Site

Seoul, 5030, South Korea
GSK Investigational Site

Suwon Kyunggi-do, 16499, South Korea
GSK Investigational Site

Kaohsiung City, 807, Taiwan
GSK Investigational Site

Taichung, 40447, Taiwan
GSK Investigational Site

Taichung, 407219, Taiwan
GSK Investigational Site

Taipei, 10002, Taiwan

Conditions

Explore the condition pages connected to this study.

ASTHMA